Compugen Announces Discovery of Blood Based Biomarker for Diagnosis of Lung Cancer
Complete the form below to unlock access to ALL audio articles.
Compugen Ltd. has announced the discovery and experimental verification of CGEN-438, a potential blood based biomarker for lung cancer. CGEN-438 is splice variant peptide of delta-like protein 3 precursor (DLL3).
Importantly, the Compugen discovered biomarker is a peptide that is secreted from the cell into the bloodstream, whereas the previously known DLL3 is a protein located on the cell membrane. Initial clinical evidence indicates that the Compugen discovered molecule could potentially serve as both a serum biomarker for the diagnosis of small cell lung cancer and as a component in a biomarker combination for the diagnosis of non-small cell lung cancer patients.
Using a test developed by Compugen to detect CGEN-438 in serum, the blood levels of the peptide were measured in about 40 lung cancer patients and healthy individuals.
CGEN-438 concentrations detected in serum samples of small cell lung cancer patients were higher than those detected in controls, demonstrating its potential to become a diagnostic biomarker for small cell lung cancer. It was also evident that CGEN-438 is expressed to a large extent in certain non-small cell lung cancer serum samples and therefore may be used in a biomarker combination test for the diagnosis of non-small cell lung cancer as well. A patent application covering this biomarker has been filed by Compugen.
Similar to the recently announced CGEN-144, CGEN-438 is one of a group of putative cancer and cardiovascular biomarkers which was initially predicted in silico utilizing Compugen’s immunoassay computational discovery platform, and then further validated experimentally.
